Barclays PLC Editas Medicine, Inc. Transaction History

Barclays PLC

$353 Billion
Q1 2025

A detailed history of Barclays PLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Barclays PLC holds 141,184 shares of EDIT stock, worth $232,953. This represents 0.0% of its overall portfolio holdings.

Number of Shares

141,184

Previous 181,238 22.1%

Holding current value

$232,953

Previous $229,000 28.38%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$1.14 - $3.2 $45,661 - $128,172	-40,054 Reduced 22.1%	141,184 $164,000
Q4 2024 Feb 13, 2025	BUY	$1.2 - $3.76 $3,277 - $10,268	2,731 Added 1.53%	181,238 $229,000
Q3 2024 Nov 15, 2024	BUY	$3.39 - $5.96 $193,182 - $339,636	56,986 Added 46.89%	178,507 $607,000
Q2 2024 Aug 14, 2024	SELL	$4.67 - $7.28 $108,353 - $168,910	-23,202 Reduced 16.03%	121,521 $567,000
Q1 2024 May 15, 2024	SELL	$7.03 - $11.07 $947,039 - $1.49 Million	-134,714 Reduced 48.21%	144,723 $1.07 Million
Q4 2023 Feb 15, 2024	BUY	$6.25 - $11.11 $27,631 - $49,117	4,421 Added 1.61%	279,437 $2.83 Million
Q3 2023 Nov 07, 2023	SELL	$6.92 - $9.31 $167,948 - $225,953	-24,270 Reduced 8.11%	275,016 $2.15 Million
Q2 2023 Aug 03, 2023	BUY	$6.36 - $11.47 $153,683 - $277,161	24,164 Added 8.78%	299,286 $2.46 Million
Q1 2023 May 04, 2023	SELL	$7.03 - $11.53 $1.16 Million - $1.91 Million	-165,279 Reduced 37.53%	275,122 $1.99 Million
Q4 2022 Feb 13, 2023	BUY	$8.32 - $13.21 $1.17 Million - $1.85 Million	140,174 Added 46.69%	440,401 $3.91 Million
Q3 2022 Nov 03, 2022	BUY	$12.16 - $19.42 $3.38 Million - $5.4 Million	278,208 Added 1263.49%	300,227 $3.68 Million
Q2 2022 Aug 12, 2022	SELL	$9.99 - $21.35 $93,036 - $198,832	-9,313 Reduced 29.72%	22,019 $261,000
Q1 2022 May 16, 2022	SELL	$14.08 - $27.63 $889,320 - $1.75 Million	-63,162 Reduced 66.84%	31,332 $596,000
Q4 2021 Feb 14, 2022	BUY	$26.55 - $40.57 $99,695 - $152,340	3,755 Added 4.14%	94,494 $2.51 Million
Q3 2021 Nov 09, 2021	BUY	$39.27 - $72.94 $1.07 Million - $1.98 Million	27,145 Added 42.68%	90,739 $3.73 Million
Q2 2021 Aug 13, 2021	SELL	$31.29 - $56.64 $1.28 Million - $2.32 Million	-40,923 Reduced 39.15%	63,594 $3.6 Million
Q1 2021 May 13, 2021	BUY	$39.71 - $90.58 $3.2 Million - $7.31 Million	80,652 Added 337.95%	104,517 $4.39 Million
Q4 2020 Feb 11, 2021	SELL	$27.07 - $84.35 $625,127 - $1.95 Million	-23,093 Reduced 49.18%	23,865 $1.67 Million
Q3 2020 Nov 12, 2020	SELL	$28.06 - $37.16 $111,482 - $147,636	-3,973 Reduced 7.8%	46,958 $1.32 Million
Q2 2020 Aug 12, 2020	BUY	$18.5 - $34.34 $107,670 - $199,858	5,820 Added 12.9%	50,931 $1.51 Million
Q1 2020 May 13, 2020	SELL	$14.88 - $32.78 $424,481 - $935,115	-28,527 Reduced 38.74%	45,111 $896,000
Q4 2019 Feb 10, 2020	BUY	$19.49 - $32.63 $355,887 - $595,823	18,260 Added 32.97%	73,638 $2.18 Million
Q3 2019 Nov 14, 2019	BUY	$22.49 - $26.81 $516,797 - $616,066	22,979 Added 70.93%	55,378 $1.26 Million
Q2 2019 Aug 14, 2019	BUY	$20.48 - $27.76 $382,013 - $517,807	18,653 Added 135.7%	32,399 $802,000
Q1 2019 May 15, 2019	SELL	$19.43 - $26.41 $381,177 - $518,111	-19,618 Reduced 58.8%	13,746 $336,000
Q4 2018 Feb 14, 2019	BUY	$18.19 - $31.79 $276,178 - $482,667	15,183 Added 83.51%	33,364 $759,000
Q3 2018 Nov 14, 2018	BUY	$27.65 - $38.39 $110,434 - $153,329	3,994 Added 28.15%	18,181 $579,000
Q2 2018 Aug 14, 2018	SELL	$31.4 - $41.01 $802,332 - $1.05 Million	-25,552 Reduced 64.3%	14,187 $509,000
Q1 2018 May 15, 2018	BUY	$29.84 - $44.08 $699,031 - $1.03 Million	23,426 Added 143.6%	39,739 $1.32 Million
Q4 2017 Feb 14, 2018	BUY	$21.89 - $31.34 $76,833 - $110,003	3,510 Added 27.42%	16,313 $502,000
Q3 2017 Nov 14, 2017	BUY	$15.81 - $24.01 $202,415 - $307,400	12,803	12,803 $307,000

Others Institutions Holding EDIT

# of Institutions

218

Shares Held

48.4M

Call Options Held

436K

Put Options Held

324K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $113M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account